Idelalisib

• Idelalisib is an oral medication approved for treating certain B-cell blood cancers, including chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL).
• Its primary mechanism involves inhibiting phosphoinositide 3-kinase (PI3K) delta, a protein crucial for the growth and survival of these cancer cells.
• Common side effects can include diarrhea, fever, and nausea, while serious warnings highlight risks such as severe liver toxicity, colitis, and infections.
• This targeted therapy offers an important option for patients who have not responded to other treatments or for whom other treatments are not suitable.

What is Idelalisib and What is it Used For?

Idelalisib is a prescription medication classified as a kinase inhibitor. It is specifically approved for the treatment of certain B-cell malignancies. This targeted therapy works by inhibiting a specific enzyme that plays a critical role in the growth and survival of cancerous B-cells.

Regarding what is idelalisib used for, it is indicated for adult patients with relapsed chronic lymphocytic leukemia (CLL), relapsed follicular lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For CLL, it is often used in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. For FL and SLL, it is typically used in patients who have received at least two prior systemic therapies and whose disease has not responded to other treatments.

Comprehensive idelalisib drug information emphasizes its role as a second-line or later therapy, highlighting its importance for patients with limited treatment options. As an oral medication, it offers a convenient administration route, though close monitoring by healthcare professionals is essential due to its potent effects and potential for significant side effects.

Idelalisib Mechanism of Action

The idelalisib mechanism of action involves the selective inhibition of phosphoinositide 3-kinase delta (PI3K-delta). PI3K-delta is an enzyme that is highly expressed in B-cells and plays a crucial role in various cellular functions, including cell proliferation, survival, migration, and adhesion. In many B-cell lymphomas and leukemias, the PI3K-delta pathway is overactive, contributing to the uncontrolled growth and survival of cancer cells.

By blocking PI3K-delta, Idelalisib disrupts these critical signaling pathways within malignant B-cells. This inhibition leads to a reduction in cell proliferation, induction of apoptosis (programmed cell death), and inhibition of cell migration and adhesion, ultimately hindering the progression of the cancer. This targeted approach minimizes damage to healthy cells compared to traditional chemotherapy, though it still carries specific risks due to its impact on immune cell function.

Idelalisib Side Effects and Warnings

Like all medications, idelalisib side effects and warnings are important considerations for patients and healthcare providers. Common side effects can include gastrointestinal issues and systemic reactions. It is crucial for patients to report any new or worsening symptoms to their doctor immediately.

Common side effects associated with Idelalisib may include:

• Diarrhea or colitis
• Fever
• Nausea and vomiting
• Fatigue
• Rash
• Pneumonia and other infections
• Elevated liver enzymes

Serious warnings associated with Idelalisib include severe and fatal hepatotoxicity (liver damage), severe diarrhea or colitis, pneumonitis (inflammation of the lungs), and intestinal perforation. There is also an increased risk of serious and fatal infections, including opportunistic infections, due to its immunosuppressive effects. Patients should be closely monitored for signs of these severe adverse reactions, and treatment may need to be interrupted or discontinued based on their severity. Regular blood tests, especially for liver function and blood cell counts, are essential throughout treatment with Idelalisib.